Cytomegalovirus Ventriculoencephalitis after Unrelated Double Cord Blood Stem Cell Transplantation with an Alemtuzumab-containing Preparative Regimen for Philadelphia-positive Acute Lymphoblastic Leukemia.
10.3346/jkms.2010.25.4.630
- Author:
Seok LEE
1
;
Si Hyun KIM
;
Su Mi CHOI
;
Dong Gun LEE
;
Sung Yong KIM
;
Jong Wook LEE
;
Woo Sung MIN
;
Wan Shik SHIN
;
Chun Choo KIM
Author Information
1. Catholic Hematopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea. leeseok@catholic.ac.kr
- Publication Type:Case Reports
- Keywords:
Alemtuzumab;
Cord Blood Stem Cell Transplantation;
Cytomegalovirus;
Encephalitis;
Leukemia
- MeSH:
Antibodies, Monoclonal/pharmacology/*therapeutic use;
Antibodies, Monoclonal, Humanized;
Antibodies, Neoplasm/pharmacology/*therapeutic use;
Antineoplastic Agents/pharmacology/*therapeutic use;
Cord Blood Stem Cell Transplantation/*adverse effects;
Cytomegalovirus/drug effects;
Cytomegalovirus Infections/*drug therapy/*etiology/physiopathology;
*Encephalitis/etiology/pathology/virology;
Fatal Outcome;
Humans;
Male;
*Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications/drug therapy/virology;
Transplantation Conditioning/methods
- From:Journal of Korean Medical Science
2010;25(4):630-633
- CountryRepublic of Korea
- Language:English
-
Abstract:
Despite the prophylaxis and preemptive strategies using potent antiviral agents, cytomegalovirus (CMV) remains a major infectious cause of morbidity and mortality in allogeneic stem cell transplantation (SCT) recipients. Delayed immune reconstitution after SCT, such as cord blood and T-cell depleted SCT with the use of alemtuzumab, has been associated with an increased frequency of CMV disease as well as CMV reactivation. CMV disease involving central nervous system is an unusual presentation in the setting of SCT. We report a case of CMV ventriculoencephalitis after unrelated double cord blood SCT with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia.
